Tarsus Pharmaceuticals, Inc.
General ticker "TARS" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $2.0B (TTM average)
Tarsus Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 42.3%.
Estimated limits based on current volatility of 1.8%: low 79.22$, high 82.14$
Factors to consider:
- Total employees count: 323 (+32.4%) as of 2024
- Top business risk factors: Regulatory and compliance, Operational and conduct risks, Limited product diversification, Disaster recovery and infrastructure issues, Transition to commercialization
- Current price 26.5% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [30.73$, 64.67$]
- 2025-12-31 to 2026-12-31 estimated range: [22.85$, 50.21$]
Financial Metrics affecting the TARS estimates:
- Negative: with PPE of -17.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.09 <= 0.33
- Positive: 41.86 < Shareholder equity ratio, % of 59.56 <= 63.39
- Negative: negative Net income
- Positive: -14.38 < Investing cash flow per share per price, % of -9.82
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -13.70 <= -0.75
Short-term TARS quotes
Long-term TARS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $25.82MM | $17.45MM | $182.95MM |
| Operating Expenses | $88.53MM | $160.60MM | $303.52MM |
| Operating Income | $-62.71MM | $-143.16MM | $-120.57MM |
| Non-Operating Income | $0.62MM | $7.26MM | $5.01MM |
| Interest Expense | $2.20MM | $3.35MM | $7.85MM |
| R&D Expense | $42.62MM | $50.31MM | $53.39MM |
| Income(Loss) | $-62.09MM | $-135.89MM | $-115.55MM |
| Taxes | $-0.00MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-62.09MM | $-135.89MM | $-115.55MM |
| Stockholders Equity | $192.90MM | $196.99MM | $224.53MM |
| Inventory | $0.00MM | $3.11MM | $2.62MM |
| Assets | $227.86MM | $265.49MM | $376.99MM |
| Operating Cash Flow | $-49.03MM | $-117.49MM | $-83.03MM |
| Capital expenditure | $0.51MM | $5.50MM | $1.57MM |
| Investing Cash Flow | $-144.63MM | $140.60MM | $-199.19MM |
| Financing Cash Flow | $93.99MM | $130.18MM | $154.66MM |
| Earnings Per Share** | $-2.52 | $-4.62 | $-3.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.